25.10.2010 • NewsDAK AmericasEastmanPET

Eastman Sells PET Business to DAK Americas

Eastman Chemical Company has entered into a definitive agreement with DAK Americas to sell the PET business and related assets and technology of its Performance Polymers segment. The transaction is expected to close during Q4 of 2010. The total cash proceeds of the transaction are expected to be $600 million, with the final purchase price subject to working capital adjustments at closing. The company expects to recognize a modest gain from the sale.

Three months ago, Eastman reported continued difficult market conditions for PET in North America, which limited the ability to offset higher raw material and energy costs with higher selling prices. In conjunction with the sale of the Performance Polymers PET business, the company has approved a restructuring plan to reduce costs and will recognize severance restructuring charges in the fourth quarter.

Not so long ago, in March 2010 Eastman filed a lawsuit against DAK Americas in connection with their unauthorized use of IntegRex PET technology.

 

Company

Eastman Chemical Company

200 South Wilcox Drive
37662 Kingsport

Company contact







Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

most read

Photo
21.03.2025 • News

What’s Next for Pharma Supply Chains?

Sudden shifts in demand, supply shortages and global collapse have put immense pressure on pharmaceutical logistics. To address these challenges, PHARMAP 2025 brings together industry experts to discover AI-driven supply chain optimisation, strategic logistics partnerships and digital solutions that enhance efficiency and resilience in the pharmaceutical supply chain.